JP2006527232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006527232A5 JP2006527232A5 JP2006515900A JP2006515900A JP2006527232A5 JP 2006527232 A5 JP2006527232 A5 JP 2006527232A5 JP 2006515900 A JP2006515900 A JP 2006515900A JP 2006515900 A JP2006515900 A JP 2006515900A JP 2006527232 A5 JP2006527232 A5 JP 2006527232A5
- Authority
- JP
- Japan
- Prior art keywords
- glutaminase
- compound
- activity
- preparation according
- anthracyclines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010073324 Glutaminase Proteins 0.000 claims 6
- 102000009127 Glutaminase Human genes 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229940034982 antineoplastic agent Drugs 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108010033586 polyethylene glycol-glutaminase-asparaginase Proteins 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 108010092160 Dactinomycin Proteins 0.000 claims 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 241000589516 Pseudomonas Species 0.000 claims 1
- 241000920685 Pseudomonas sp. 7A Species 0.000 claims 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 229960000640 dactinomycin Drugs 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001156 mitoxantrone Drugs 0.000 claims 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10326821A DE10326821A1 (de) | 2003-06-11 | 2003-06-11 | Pharmazeutische Kombinationspräparate zur Krebstherapie |
| PCT/EP2004/006320 WO2004108153A1 (de) | 2003-06-11 | 2004-06-11 | Pharmazeutische kombinationspräparate zur krebstherapie enthaltend glutaminase und antineoplastische anthracycline oder platinverbindungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006527232A JP2006527232A (ja) | 2006-11-30 |
| JP2006527232A5 true JP2006527232A5 (cg-RX-API-DMAC7.html) | 2007-06-21 |
Family
ID=33495036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006515900A Pending JP2006527232A (ja) | 2003-06-11 | 2004-06-11 | グルタミナーゼ及び抗新生物性のアントラサイクリン類又は白金化合物を含有する癌治療のための薬剤学的な組合せ製剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060263346A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1633394B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2006527232A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE350054T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004244755B9 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2528897A1 (cg-RX-API-DMAC7.html) |
| DE (2) | DE10326821A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2280972T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004108153A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2651691A1 (en) * | 2006-05-10 | 2007-11-15 | Medical Enzymes Ag | Glutaminase and 6-diazo-5-oxo-l-norleucine (don) for cancer therapy |
| US8178564B2 (en) | 2006-11-06 | 2012-05-15 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8173686B2 (en) | 2006-11-06 | 2012-05-08 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168662B1 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| US8168661B2 (en) | 2006-11-06 | 2012-05-01 | Poniard Pharmaceuticals, Inc. | Use of picoplatin to treat colorectal cancer |
| EP2047858A1 (en) * | 2007-10-10 | 2009-04-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Combination products for treating cancer |
| CN105960405B (zh) | 2014-01-06 | 2021-02-19 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020094542A1 (en) * | 1988-04-15 | 2002-07-18 | Peter Leskovar | Drugs and methods for treating cancer |
| US4955857A (en) * | 1988-07-18 | 1990-09-11 | Shettigar Udipi R | Multi-enzyme bioreactor therapy for cancer |
| US5776458A (en) * | 1990-12-05 | 1998-07-07 | Pharmacia & Upjohn S.P.A. | Anthracycline-conjugates |
| DE4140003C2 (de) * | 1991-12-04 | 1994-09-29 | Joseph Prof Dr Roberts | Gentechnisch hergestellte Glutaminase und ihre Verwendung bei der antiviralen und Anti-Krebstherapie |
| CA2149922C (en) * | 1992-12-04 | 2007-05-15 | Thomas W. Macallister | Genetically engineered glutaminase and its use in antiviral and anticancer therapy |
| EP0613899B1 (en) * | 1993-03-04 | 2003-01-15 | Matsushita Electric Industrial Co., Ltd. | Cocaine derivative, protein conjugate thereof, monoclonal antibody producing hybridoma cell line, method for preparing the hybridoma cell line and monoclonal antibody |
| US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
| US6200754B1 (en) * | 1998-03-19 | 2001-03-13 | Variagenics, Inc. | Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes |
| WO2003039327A2 (en) * | 2001-11-02 | 2003-05-15 | Dana-Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof |
| WO2003039545A2 (en) * | 2001-11-07 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma and others cancers |
-
2003
- 2003-06-11 DE DE10326821A patent/DE10326821A1/de not_active Ceased
-
2004
- 2004-06-11 CA CA002528897A patent/CA2528897A1/en not_active Abandoned
- 2004-06-11 DE DE502004002561T patent/DE502004002561D1/de not_active Expired - Lifetime
- 2004-06-11 JP JP2006515900A patent/JP2006527232A/ja active Pending
- 2004-06-11 EP EP04739811A patent/EP1633394B1/de not_active Expired - Lifetime
- 2004-06-11 AT AT04739811T patent/ATE350054T1/de active
- 2004-06-11 AU AU2004244755A patent/AU2004244755B9/en not_active Ceased
- 2004-06-11 WO PCT/EP2004/006320 patent/WO2004108153A1/de not_active Ceased
- 2004-06-11 ES ES04739811T patent/ES2280972T3/es not_active Expired - Lifetime
- 2004-06-11 US US10/560,317 patent/US20060263346A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ong et al. | Chemotherapy in malignant pleural mesothelioma. A review. | |
| CN100374162C (zh) | 海鞘素-743在制备用于治疗肿瘤的药剂中的应用 | |
| JP2006504723A5 (cg-RX-API-DMAC7.html) | ||
| WO2004062604A3 (en) | Treatment of cancer with 2-deoxyglucose | |
| JP2008519047A5 (cg-RX-API-DMAC7.html) | ||
| CA2407371A1 (en) | Quinazoline derivatives for the treatment of tumours | |
| WO2002013873A3 (en) | P97-active agent conjugates and their methods of use | |
| HUP0401174A3 (en) | Ecteinascidin analogues, their use in the preparation of a medicament for treatment of cancer and pharmaceutical compositions containing the compounds | |
| JP2006508953A5 (cg-RX-API-DMAC7.html) | ||
| WO2003032906A3 (en) | Delivery of poorly soluble drugs | |
| JP2006500346A5 (cg-RX-API-DMAC7.html) | ||
| JP2002528502A5 (cg-RX-API-DMAC7.html) | ||
| WO2006050155A3 (en) | Cancer therapeutic compositions | |
| JP2006502132A5 (cg-RX-API-DMAC7.html) | ||
| WO2011159100A2 (ko) | 항암 활성을 나타내는 약제학적 조성물 | |
| JP2005508963A5 (cg-RX-API-DMAC7.html) | ||
| JP2006514116A5 (cg-RX-API-DMAC7.html) | ||
| CA2450087A1 (en) | Benzisoselenazolonyl derivatives having antineoplastic, anti-inflammatory and antithrombotic activities as well as their use | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| JP2005530735A5 (cg-RX-API-DMAC7.html) | ||
| JP2004523517A5 (cg-RX-API-DMAC7.html) | ||
| JP2006527232A5 (cg-RX-API-DMAC7.html) | ||
| ATE364586T1 (de) | Steigerung der wirksamkeit von wirkstoffen durch micellare zubereitung mit retinolderivaten | |
| WO2002102311A3 (en) | Nanoparticles for treating targeted tissues and cells | |
| EP1609473A8 (en) | Use of acetyl-d-aminoglycosamine in treatment of local lesions and systematic symptoms related to infections of virus or bacteria |